摘要
目的:分析嗜麦芽窄食单胞菌的耐药率及有效的治疗方案。方法:采用WHONET软件对医院2013年—2014年间微生室分离的嗜麦芽窄食单胞菌对抗菌药物的耐药率作了统计,并对其感染病例治疗的有效率作了回顾性分析。结果:2013年—2014年间分离的嗜麦芽窄食单胞菌104株,其中定植菌为26株,致病菌为78株;嗜麦芽窄食单胞菌感染患者78例,其年龄≥60岁占80.76%;并且57.69%患者伴有慢性呼吸道疾病;嗜麦芽窄食单胞菌对左氧氟沙星、复方磺胺甲噁唑和米诺环素的敏感率分别为82.22%、94.74%和100.00%,其对头孢哌酮-舒巴坦的耐药率为36.84%;采用的4种治疗方案分别为β-内酰胺酶抑制剂复合制剂、第3代或第4代头孢菌素、第3代头孢菌素与左氧氟沙星联用、β-内酰胺酶抑制剂复合制剂与阿米卡星联用;治疗的总有效率分别为56.60%、60.00%、58.82%和100.00%。结论:哌拉西林-他唑巴坦、头孢哌酮-舒巴坦单独或哌拉西林-他唑巴坦与阿米卡星联用,可有效治疗嗜麦芽窄食单胞菌导致的感染。
Objective: To analyze the antibiotic resistance rates and therapeutic regimen of 104 strains of Stenotro- phomonas Maltophilia(S.maltophilia). Methods: The antibiotic resistance of S.maltophilia that was isolated from our hospital during 2013-2014 was analyzed by WHONET software; treatment outcomes for S.maltophilia bacteraernia were evaluated by retrospectively analysis. Results: Total 104 strains of S.maltophilia were isolated from year 2013 to 2014, they were divided into two groups: 26 strains were colonized only and 78 strains were infected by S.maltophilia. 80.76% of patients who were infected S.maltophilia', aged ≥60, and 57.69% of infected patients has chronic respiratory disease. About 82.22%, 94.74%, 100.00% and 36.84% of the S.maltophilia isolates had sensitivity rates to levofloxacin, trimethoprim-sulfamethoxazol, minocycline and cefoperazone-sulbactam respectively. The patients who were infected 5'. maltophilia received four treatment strategies: B-lactam-enzyme inhibitor. They received the third or the fourth genera- tion cephalosporin, the third or the fourth generation cephalosporin combination with levofloxacin and B-lactaln-en- zyme inhibitor combination with amikacin; the clinical effective rate was 56.60%, 60.00%, 58.82% and 100.00%, re- spectively. Conclusion: Piperacillin-tazobactam and cefperazone-sulbactam monotherapies or piperacillin-tazobactam combinantion with amikacin were effective for the treatment orS. maltophilia infections.
出处
《抗感染药学》
2015年第3期371-374,共4页
Anti-infection Pharmacy
基金
佛山市卫生局医学科研基金项目(编号:2014238)
关键词
嗜麦芽窄食单胞菌
定植菌
致病菌
耐药率
治疗方案
Stenotrophomonas maltophilia
colonized bacteria
pathogenic bacteria
resistance rates
therapeutic regimen